OWC Pharmaceutical Research (OWC Pharmaceutical Research) ROCE % : -154.02% (As of Sep. 2019)

View and export this data going back to 2008. Start your Free Trial

What is OWC Pharmaceutical Research ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. OWC Pharmaceutical Research's annualized ROCE % for the quarter that ended in Sep. 2019 was -154.02%.

OWC Pharmaceutical Research ROCE % Historical Data

The historical data trend for OWC Pharmaceutical Research's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

OWC Pharmaceutical Research ROCE % Chart

OWC Pharmaceutical Research Annual Data

Trend

Dec08

Dec11

Dec12

Dec13

Dec14

Dec15

Dec16

Dec17

Dec18

ROCE %

Get a 7-Day Free Trial

-757.97

-184.99

-623.48

-797.55

-525.09

OWC Pharmaceutical Research Quarterly Data
	Dec14	Mar15	Jun15	Sep15	Dec15	Mar16	Jun16	Sep16	Dec16	Mar17	Jun17	Sep17	Dec17	Mar18	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19
ROCE %	Get a 7-Day Free Trial															-64.44	-870.14	-112.76	-134.30	-154.02

OWC Pharmaceutical Research ROCE % Calculation

OWC Pharmaceutical Research's annualized ROCE % for the fiscal year that ended in Dec. 2018 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2018 )		(A: Dec. 2017 )		(A: Dec. 2018 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2018 )		(A: Dec. 2017 )		(A: Dec. 2018 )
	=	-10.255	/	( ( (1.061 - 0.27)	+	(3.553 - 0.438) )	/ 2 )
	=	-10.255	/	( (0.791	+	3.115)	/ 2 )
	=	-10.255	/	1.953
	=	-525.09 %

OWC Pharmaceutical Research's ROCE % of for the quarter that ended in Sep. 2019 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2019 )		(Q: Jun. 2019 )		(Q: Sep. 2019 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2019 )		(Q: Jun. 2019 )		(Q: Sep. 2019 )
	=	-2.348	/	( ( (2.335 - 0.516)	+	(1.773 - 0.543) )	/ 2 )
	=	-2.348	/	( ( 1.819	+	1.23 )	/ 2 )
	=	-2.348	/	1.5245
	=	-154.02 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2019) EBIT data.

OWC Pharmaceutical Research (OTCPK:OWCP) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

OWC Pharmaceutical Research ROCE % Related Terms

Thank you for viewing the detailed overview of OWC Pharmaceutical Research's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

OWC Pharmaceutical Research (OWC Pharmaceutical Research) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » OWC Pharmaceutical Research Corp (OTCPK:OWCP) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

2 Ben Gurion Street, Ramat Gan, ISR, 5257334

Website

http://www.owcpharma.com

OWC Pharmaceutical Research Corp is a medical cannabis research and development company. The firm through its subsidiary researches and develops cannabis-based products and treatments specifically designed for multiple myeloma, psoriasis, fibromyalgia, post-traumatic stress disorder (PTSD), migraine, sexual function and skin disorders. It also provides consulting services to governmental and private entities to assist them with developing and implementing tailor-made medical cannabis program.

Executives

Asher Zwebner

director, officer: CHIEF FINANCIAL OFFICER

CDOOR CORPORATION, 20 A REHOV SHAREI TORAH BAYIT VEGAN, JERUSALEM L3 96387